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Abstract
Background: Globally, 40% of all tuberculosis (TB) cases, 65% paediatric cases and 75% multi-drug resistant TB
(MDR-TB) cases are missed due to underreporting and/or under diagnosis. A recent Kenyan TB prevalence survey
found that a significant number of TB cases are being missed here. Understanding spatial distribution and patterns
of use of TB diagnostic tests as per the guidelines could potentially help improve TB case detection by identifying
diagnostic gaps.
Methods: We used 2015 Kenya National TB programme data to map TB case notification rates (CNR) in different
counties, linked with their capacity to perform diagnostic tests (chest x-rays, smear microscopy, Xpert MTB/RIF®,
culture and line probe assay). We then ran hierarchical regression models for adults and children to specifically
establish determinants of use of Xpert® (as per Kenyan guidelines) with county and facility as random effects.
Results: In 2015, 82,313 TB cases were notified and 7.8% were children. The median CNR/100,000 amongst 0-14yr
olds was 37.2 (IQR 20.6, 41.0) and 267.4 (IQR 202.6, 338.1) for ≥15yr olds respectively. 4.8% of child TB cases and 12.
2% of adult TB cases had an Xpert® test done, with gaps in guideline adherence. There were 2,072 microscopy sites
(mean microscopy density 4.46/100,000); 129 Xpert® sites (mean 0.31/100,000); two TB culture laboratories and 304
chest X-ray facilities (mean 0.74/100,000) with variability in spatial distribution across the 47 counties. Retreatment
cases (i.e. failures, relapses/recurrences, defaulters) had the highest odds of getting an Xpert® test compared to
new/transfer-in patients (AOR 7.81, 95% CI 7.33-8.33). Children had reduced odds of getting an Xpert® (AOR 0.41, CI
0.36-0.47). HIV-positive individuals had nearly twice the odds of getting an Xpert® test (AOR 1.82, CI 1.73-1.92).
Private sector and higher-level hospitals had a tendency towards lower odds of use of Xpert®.
Conclusions: We noted under-use and gaps in guideline adherence for Xpert® especially in children. The under-use
despite considerable investment undermines cost-effectiveness of Xpert®. Further research is needed to develop
strategies enhancing use of diagnostics, including innovations to improve access (e.g. specimen referral) and
overcoming local barriers to adoption of guidelines and technologies.
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Background
Globally, there is a significant TB case detection gap:
40% of all tuberculosis (TB) cases, 65% paediatric cases
and 75% multi-drug resistant TB (MDR-TB) cases are
missed due to a mixture of underreporting and under
diagnosis [1–3]. Rapid and accurate diagnosis of TB is
critical for timely initiation of treatment to prevent
death [4–6]. A recent prevalence survey in Kenya found
higher rates of TB than previously thought (558/
100,000), with up to 55% of cases being missed probably
due to under-detection [7]. Three quarters of the posi-
tive TB cases identified in the survey reported seeking
care for TB-like symptoms but were not diagnosed. The
survey recruited ≥15yr olds, but extrapolation from adult
data showed that two thirds of paediatric TB cases were
missed [7]. Notification data may underestimate child
TB incidence, which may be explained in part by poor
reporting of diagnosed paediatric cases [8]; and chal-
lenges of diagnosing TB in children due to paucibacillary
disease and difficulty obtaining suitable samples [9, 10].
Quicker, more sensitive TB diagnostic technologies are
being introduced globally [4, 11]. In 2010, Xpert MTB/
RIF® was initially endorsed by the World Health Organ-
isation (WHO) for children, the HIV infected and sus-
pected MDR-TB cases [12], but is now recommended as
the first line diagnostic test for all presumed TB cases
[13, 14]. Kenya introduced Xpert® in 2011. According to
the guidelines used in Kenya in 2015 (when this study
was done), all presumptive paediatric, HIV-infected
smear negative, drug resistant (DR) cases, or retreatment
cases i.e. relapse (recurrence)/defaults/treatment failures
should have had at least one Xpert® assay as part of their
diagnostic work up (Additional file 1) [15, 16]. By 2015,
there were 129 machines distributed throughout the
country (146 machines to date), with more expected
[17]. Optimal use of Xpert® is important for TB case de-
tection [18, 19]. Few studies have specifically reviewed
spatial distribution and practices in the utilisation of
bacteriological TB diagnostic tests like Xpert® comparing
adults and children, in countries that carry a high TB/
MDR burden like Kenya.
A multi-country study on gaps in reporting paediatric
TB found children were rarely considered for testing
[20]. Age, gender, poverty and literacy are known to in-
fluence general health care utilisation and demand for
services [21, 22]. One study found socioeconomic status
and prior anti-TB treatment were strong determinants
of utilisation of bacteriological tests [23]. Behavioural or
health system issues may also play a role where services
are available but underutilised- perhaps due to patients’
lack of awareness or perceived poor quality [22, 24–26].
Seeking to understand and improve TB case detection
in Kenya, we set out to: describe the characteristics and
spatial distribution of TB cases reported to the TB
programme; the availability, distribution and patterns of
use of TB diagnostic tests as per Kenyan guidelines [15, 16];
and to establish the determinants of use of Xpert®, noting
differences in adults and children in the various counties.
To the best of our knowledge, this is the first attempt to de-
scribe in detail the utilisation of TB diagnostics in Kenya,
comparing adults and children to try to unmask the “hid-
den epidemic” of TB [27]. Findings will hopefully help
guide policy makers on where the greatest needs are, how
well guidelines are being implemented and offer sugges-
tions to mitigate gaps identified. As new tests emerge [28],
understanding patterns and determinants of use could help
reduce TB deaths by guiding early diagnosis and linkage to
appropriate treatment.
Methods
Setting
Kenya is administratively divided into 47 counties, that
are now largely responsible for health care since devolu-
tion in 2013 [29]. Health services are provided by public,
private, non-profit non-governmental organisations
(NGO) and faith based organisations (FBO). The health-
care system is structured in a hierarchical manner, start-
ing with primary healthcare in the community and
complicated cases referred upwards to secondary and
tertiary levels of healthcare [29]. According to the
Kenyan Master Facility List, there are approximately
10,000 health facilities in the country and just about half
are TB treatment sites [30–32]. For this analysis, we ag-
gregated TB health facilities into two: lower level (dis-
pensaries, health centres, and maternity/nursing homes)
for primary care; and higher level (county hospitals and
national referral facilities) that provide secondary and
tertiary referral services.
Study Population
We included patients of all ages who were notified to
the Kenya National TB programme and started TB
treatment in 2015.
Study variables
We wished to explore the possible influence on use of
Xpert MTB/RIF® of variables in three hierarchical levels:
county, health facility and individual. Individual level
co-variates included: age; gender; HIV status; nutritional
status; and type of TB patient i.e. new/transfer-in or
retreatment cases (relapse/defaults/treatment failures).
An age cut-off of 15yrs for children is used locally and
internationally for TB programming [14], therefore
“child” here refers to 0-14yr olds. For nutrition status,
weight-for-age Z (WAZ) scores were computed for those
aged 0-23yr and body mass index (BMI) truncated at -5
to +5SD for those ≥10yr, and patients classified as
underweight according to the scores. Those 10-23yr who
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met criteria of underweight by either criterion were also
classified as underweight. Health facility level co-variates
included: sector of care (public, private, or FBOs), level
of care provided (higher vs lower level) and whether they
were an Xpert® site or not. County level co-variates in-
cluded: poverty; maternal education levels; travel time to
nearest health facilities; and availability of Xpert® facil-
ities per 100,000. All co-variates were determined for
each of the 47 counties for 2015. These factors were
decided upon a priori following review of literature on
drivers of use of TB and health care services in general
and data availability [21, 22].
The primary outcome of interest was evidence of
Xpert® being done in patients who had been started on
TB treatment. According to the 2015 Kenyan guidelines,
all presumptive paediatric, HIV-infected smear negative,
drug resistant (DR) cases, or retreatment cases i.e. re-
lapse (recurrence)/defaults/treatment failures should
have had at least one Xpert® assay as part of their diag-
nostic work up (Additional file 1) [15, 16].
Data sources
We considered the best data sources for the three levels
of variables of interest. For the individual level,
de-identified data from the Kenya National TB
Programme patients’ treatment register for 2015 were
used (patients who were notified and/or started treat-
ment in 2015). TB case definitions were as per Guidance
for National TB programmes (Additional file 1) [33].
Health facility level data were from the Kenya Master
Health Facility list [30] and Kenya Services Availability
and Readiness Assessment Mapping Report (SARAM)
2014 [34]. Health facilities in the national TB register
were geocoded using KEMRI-Wellcome Trust’s Kenya
Health Facilities Database, which was last updated in
2016 using online digital place-name gazetteers and
Global Positioning System (GPS) sources. County level
data were from each county governments’ integrated
development plans for 2015 [35]. The projected 2015
Kenya gridded population distribution surface at 100m
spatial resolution was obtained from the WorldPop
project [36, 37].
Statistical and Spatial Analysis
Stata version 15MP (StataCorp.2017, College Station,
TX, USA) and ArcGIS 10.5 (ESRI, Redlands, CA, USA)
were used for statistical analysis, and mapping and
spatial analysis respectively. We described the propor-
tion of adults and children reported to the TB
programme, their socio-demographic characteristics, use
of TB diagnostic tests and outcomes. We used the 2015
Kenya National TB programme data to construct maps
for each TB case notification rate (CNR) in different
counties and linked this with their capacity to perform
diagnostic tests (chest x-rays, smear microscopy, Xpert®,
culture and line probe assay) from the SARAM report [34].
For adherence to guidelines, we only had data for
those who had tests done, and used these patients to de-
scribe patterns of use of TB diagnostic tests. Co-variates
of theoretical and/or statistical significance were used to
build hierarchical logistic regression models to establish
determinants of use of Xpert® in adults and children.
Possible collinearity was assessed using the variance in-
flation factor (VIF). Variables with VIF less than 10 were
considered for analysis. The models converged at five in-
tegration points for complete case analysis, with county
and health facility as random effects [38]. Models were
built for the 0-14yrs and ≥15yrs separately and a model
for the total population, with likelihood ratio tests, ex-
ploration for interactions in pre-specified covariates
(HIV and nutrition status) and quantile-quantile plots of
residuals used to determine best fit as seen in Additional
file 2 [38, 39].
Results
Data were available from 82,313 patients who started TB
treatment in 2015. Table 1 gives the characteristics of
these patients for the different age bands and overall
population. There were 6,450 children aged 0-14yr, and
they represented 7.8% of the total population. In the
overall population, 62.4% (51,337) were male, and they
were 3,406 (52.8%) in the 0-14yr group. Most of the pa-
tients were from the public sector. TB was pulmonary in
approximately three quarters of all the patients. A quar-
ter of patients 0-14yrs were HIV infected compared with
a third of those ≥15yrs. Overall, close to half the patients
were underweight. Close to 10% of those ≥15yrs needed
TB retreatment (i.e. failures, relapses/recurrences, de-
faulters). Less than 5% (309/6,450) of patients 0-14yrs
and 12.2% (9,224/75,863) of patients ≥15yrs had an
Xpert® done. The proportion of positive Xpert® tests was
63.1% (195/309) for the 0-14yr and 81.2% (7,493/9,224)
for the ≥15yrs old; while microscopy was positive in
36.7% (694/1,886) vs 67.1% (40,768/60,797) for 0-14yrs
vs the ≥15yrs respectively. Overall case fatality was be-
tween 4-6% for both groups.
Patterns of use of TB diagnostics tests
Figure 1 illustrates diagnostic practices amongst those
patients who were started on anti-TB treatment. More
than a third of children 0-14yr had no diagnostic test
done, and were started on treatment based on clinical
diagnosis only. Chest X-ray was the commonly used test
in this age group (37.1%); while microscopy was the
commonest amongst the ≥15yrs. Table 2 illustrates the
patterns of use of bacteriological tests amongst those
who had these tests done, relating them to the 2015
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Table 1 Characteristics of Patients notified to the Kenyan National TB Programme in 2015
0-14yrs n (%) ≥15yrs n (%) Overall population n (%)
(N = 6450) (N = 75863) (N = 82313)
Gender
Male 3406 (52.8) 47931 (63.2) 51337 (62.4)
Female 3044 (47.2) 27932 (36.8) 30976 (37.6)
Sector
Public 4938 (76.6) 59165 (78.0) 64103 (77.9)
Prisons 41 (0.6) 1349 (1.8) 1390 (1.7)
Private 1343 (20.8) 14010 (18.5) 15353 (18.7)
Faith based and others 128 (2.0) 1339 (1.8) 1467 (1.8)
TB Type
Pulmonary 4774 (74.0) 62964 (83.0) 67738 (82.3)
Extra-pulmonary 1676 (26.0) 12899 (17.0) 14575 (17.7)
HIV testing
Negative 4517 (70.0) 49016 (64.6) 53533 (65.0)
Positive 1610 (25.0) 24980 (32.9) 26590 (32.3)
Unknown 323 (5.0) 1867 (2.5) 2190 (2.7)
Anthropometry (BMI)
Underweighta 2951 (45.8) 35274 (46.5) 38225 (46.4)
Normal 2777 (43.1) 31338 (41.3) 34115 (41.5)
Overweight/obese 22 (0.34) 2929 (3.9) 2951 (3.4)
Undocumented 700 (10.9) 6322 (8.3) 7022 (8.5)
Type of patient
New 6233 (96.6) 68470 (90.3) 74703 (90.8)
Transfer in 40 (0.6) 788 (1.0) 828 (1.0)
Relapse (recurrence) 144 (2.2) 5383 (7.1) 5527 (6.7)
Default 33 (0.5) 999 (1.3) 1032 (1.3)
Failure 0 (0) 223 (0.3) 223 (0.3)
Chest-X-ray
Done 3140 (48.7) 22141 (29.2) 25281 (30.7)
Not done 3310 (51.3) 53722 (70.8) 57032 (69.3)
Smear Microscopy
Done 1886 (29.2) 60797 (80.1) 62,683 (76.2)
Positiveb 694 (36.7) 40768 (67.1) 41462 (66.1)
Negativeb 1192 (63.2) 20029 (32.9) 21221 (33.9)
Xpert MTB/RIF®
Done 309 (4.8) 9224 (12.2) 9533 (11.6)
Positive (Rif-Sensitive)b 195 (63.1) 7493 (81.2) 7688 (80.6)
Positive (Rif-Resistant)b 1 (0.3) 129 (1.4) 130 (1.4)
Negativeb 113 (36.6) 1602 (17.4) 1715 (18.0)
Culture/Line Probe Assay (LPA)
Done 5 (0.1) 444 (0.6) 449 (0.5)
Drug susceptibleb 5 (100) 371 (83.6) 376 (83.7)
Drug resistantb 0 (0.0) 73 (16.4) 73 (16.3)
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Kenyan guidelines (Additional file 1). Children 0-14yr
represented <5% of those who had either Xpert® or
Microscopy or Culture/LPA done. Those with extra-
pulmonary TB also rarely got any of the tests done.
Retreatment cases got a culture/LPA done more than any
other test. Forty one percent of the patients got Xpert® as
per guidelines, with better guideline adherence for cul-
ture/LPA (61.2%) and microscopy (97.8%), respectively.
Tuberculosis Case Notification Rates and distribution of
TB cases in Kenya
Figures 2 and 3 and Additional files 3 and 4 show case
notification rates (CNR) by age group and county, as
well as variation in county use of Xpert® and microscopy.
Median age was 32yr (IQR 24yr, 43yr). The highest CNR
was amongst those 35-44yrs (455/100,000), and the
lowest amongst the 5-9yrs (27/100,000) Fig. 2. The me-
dian CNR/100,000 amongst children 0-14yr old was 37.2
(IQR 20.6, 41.0) and 267.4 (IQR 202.6, 338.1) for ≥15yr
olds respectively. Median use of Xpert® among 0-14yr
olds was 1.45/100,000 (IQR 0.7, 2.1) and in ≥15yr olds
was 29.9/100,000 (IQR 21.0, 42.8). Median use of mi-
croscopy among 0-14yr olds was 8.1/100,000 (IQR 6.6,
12.8) and 222/100,000 (IQR 169.8, 270.4) in ≥15yr olds.
Xpert® use did not correlate with increase in county TB
CNR/100,000 (Fig. 3 and Additional file 4) and in this
was also observed in the univariate analysis where coun-
ties with higher Xpert® density did not have significantly
higher CNRs (Additional file 2). Microscopy use in the
≥15yr tended to be higher in counties with highest CNRs
(Fig. 3 and Additional file 4).
Figure 4 shows a panel of maps illustrating spatial dis-
tribution of TB patients in Kenya. The counties with two
Table 1 Characteristics of Patients notified to the Kenyan National TB Programme in 2015 (Continued)
0-14yrs n (%) ≥15yrs n (%) Overall population n (%)
(N = 6450) (N = 75863) (N = 82313)
Outcome
Cured 537 (8.3) 31416 (41.4) 31953 (38.8)
Died 270 (4.2) 4391 (5.8) 4661 (5.7)
Treatment failure 1 (0.02) 429 (0.6) 430 (0.5)
Otherc 5642 (87.5) 39627 (52.2) 45269 (55%)
aUnderweight defined as either WAZ <-2SD or BMI<18.5 as appropriate for age
bPercentage in brackets represent proportions amongst those who got the test done
cOther included: treatment not completed; completed but not cured; defaulted; transferred out
Fig. 1 Diagnostic practices amongst patients started on TB treatment in 2015
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large cities had some of the highest CNRs, as did two
counties serving the pastoralist communities of the
northern and eastern frontiers (panel A). Panel B and C
show the CNRs in the ≥15yr olds (“Adults”) and in chil-
dren 0-14yr old respectively, while D shows the ratio of
adult to child TB cases. These maps highlight some of
the adult hot spots with low child CNRs and ensuing
differences in adult: child ratios highlighting the gaps in
case detection for children.
Figure 5 and Additional file 5 show the distribution of
facilities with TB diagnostic facilities (Microscopy-Map A;
Xpert MTB/RIF®-Map B; Culture and Line Probe Assay-
Map C; and chest X Ray-Map D) overlaid with each
county’s total population density. In 2015, there were 129
facilities providing Xpert® services (mean Xpert® density of
0.28/100,000); 304 chest X ray facilities (mean density 0.67/
100,000); and 2,072 facilities with microscopy services
(mean density 4.54/100,000). There were disparities noted
in the distribution of Xpert® (panel B) and chest X-ray
(panel D) facilities with some northern and eastern counties
of Kenya having low facility densities/100,000 yet they carry
a high burden of TB cases (Fig. 4).
Table 2 Patterns of use of TB diagnostics and compared to recommended Kenyan TB guidelines in use in 2015
Characteristic Xpert® donea
N = 9,553
Microscopy doneb
N= 62,683
Culture/LPA donec
N = 515
n (%) n (%) n (%)
Age
0-14yr 309 (3.2) 1886 (3.0) 5 (1.0)
≥15yr 9224 (96.8) 60797 (97.0) 510 (99.0)
Gender
Male 6152 (64.5) 40128 (64.0) 385 (74.8)
Type of TB
Pulmonary 9205 (96.6) 61320 (97.8) 508 (98.6)
Extrapulmonary 328 (3.4) 1363 (2.2) 7 (1.4)
Type of patient
New/transfer in 6774 (71.1) 56821 (90.7) 200 (38.8)
Retreatment (relapse/defaults/treatment failures) 2759 (28.9) 5862 (9.3) 315 (61.2)
Test done as per guideline 3909a (41.0) 61320b (97.8) 315c (61.2)
Excerpt from 2015 Kenyan guidelines
aXpert® recommended for all presumptive paediatric TB OR HIV-infected smear negative OR drug resistant cases OR retreatment cases i.e. relapse/defaults/
treatment failures in adults OR suspected drug resistant TB
bMicroscopy recommeded for all recommended pulmonary tuberculosis cases
cCulture/LPA recommended for retreatment cases ((i.e. relapse/defaults/treatment failures) regardless of age
Fig. 2 TB Case Notification Rates (CNRs) for different age group bands in Kenya
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Determinants of use bacteriological TB diagnostic tests
comparing adults and children
Additional file 2 shows the univariate analysis of the fac-
tors that had been considered for the model building, and
Table 3 shows the final adjusted hierarchical models of de-
terminants of use of Xpert® in adults and children, with
county and health facility as random effects. Amongst in-
dividual level factors, the retreatment cases (i.e. failures,
relapses/recurrences, defaulters) had the highest odds of
getting an Xpert® (total population AOR 7.81, 95% CI 7.33
to 8.33). From the model of the total population, children
had reduced odds of getting an Xpert® test (AOR 0.41, CI
0.36 to 0.47), while being male was associated with in-
creased odds in all age groups. Overall, the HIV positive
individuals had nearly twice the odds of getting an Xpert®
compared to the HIV negative. Nutrition status had a
marginal effect, except in the 0-14yr olds where the
underweight group had nearly twice the odds of getting
an Xpert® compared with the well-nourished cases.
Examining factors at the facility and county levels, pa-
tients in private sector and from higher level facilities had
a tendency towards lower odds of getting tested compared
with those in public sector or lower level facilities, but this
difference was not statistically significant for the 0-14yrs
old. We also noted that counties with higher Xpert® dens-
ity did not report significantly higher CNRs. From the
intra-class correlation coefficients (ICC), county as a level
explained approximately 4 & 7% and health facility 24 &
26% of the observed variability in each adjusted model.
Discussion
We set out to describe the spatial distribution of TB pa-
tients and TB diagnostic services, and patterns of use of
TB diagnostic tests in Kenya as per the guidelines (with
emphasis on Xpert MTB/RIF®), noting differences in
children and adults. The TB case notification rate (CNR)
in children 0-14yrs was nearly eight times less than that
of those ≥15yrs, which may imply under detection. Chil-
dren are thought to represent 10-20% of the total re-
ported TB cases in high TB endemic settings like Kenya,
but we observed only 7.8% in our data [40, 41]. Low
CNR among children could additionally be explained by
underreporting due to difficulties in confirming a diag-
nosis of TB in them and poor surveillance [2].
We observed wide county variation in distribution and
use of TB diagnostic tests, as well as in case notification
rates. Some of the northern and eastern counties had high
TB CNRs, but a lower density/100,000 of facilities equipped
with TB diagnostic services. Conversely, some counties had
higher facility densities but reported lower rates of use.
Kenya’s health system has been affected by devolution and
decentralisation of health services, and this could be having
a bearing on TB care [42]. A recently published patient
pathway analysis in Kenya found distinct variation in
Fig. 3 Chart showing variability of County TB CNRs and use of Xpert® and Microscopy per 100,000 population comparing adults and children
(Full county names and variables in Additional file 4)
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diagnostic and treatment availability across counties and fa-
cility levels [32].
To comply with existing guidelines at the time, all pre-
sumed child TB cases, HIV infected adults and suspected
MDR-TB cases and retreatment cases should have had at
least an Xpert® done as part of the diagnostic work up
[15, 16]. We noted underutilisation, with less than 5%
of patients 0-14yrs and 12.2% of patients ≥15yrs having
an Xpert MTB/RIF® test done, with gaps in guideline
adherence. Many children, however, had smear micros-
copy done, on a specimen that presumably could have
been used for Xpert®. The assay has much better sensi-
tivity than smear microscopy and can identify rifampi-
cin resistance with much faster turn-around time than
traditional culture, and has been shown to be cost ef-
fective [43–46]. The Kenya prevalence survey found
that when microscopy was used alone, up to 50% of TB
cases were being missed, while Xpert MTB/RIF® de-
tected 78% of TB cases [7]. While use of Xpert® is en-
couraged as the more sensitive test, it still misses
approximately 22% of TB cases, and a negative Xpert®,
especially in children does not rule out TB [43, 44].
However, if health workers can get sputum for micros-
copy especially in children, then they should ideally be
able to send the sample for Xpert®, the recommended
first-line test.
From the regression analysis, retreatment cases (i.e. fail-
ures, relapses/recurrences, defaulters) had the greatest
odds of getting an Xpert® as expected from the guidelines,
as did those who were HIV infected after adjusting for
other covariates. Children had reduced odds of getting
tested, despite the recommendation that all should have
had an Xpert®. There is, however, no documentation of
failed attempts to test.
Fig 4 Maps illustrating the spatial distribution of TB patients in various counties in Kenya by: Overall population CNR/100,000 (a); CNR/100,000 in
“adults” i.e. ≥15yrs (b); CNR/100,000 in children 0-14yrs (c); and ratio of adult: child TB CNRs (d)
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Low utilisation of Xpert® has been illustrated in other
low income, high TB burden countries both in adults
and children [47–49]. From surveys of implementation
in high TB burden countries including Kenya, reasons
associated with low utilisation included operational is-
sues like power outages and poor specimen referral;
doubts about impact to TB morbidity and mortality;
preference to trust clinical acumen; low sensitivity espe-
cially in children; challenges in getting good specimens
and false negatives; and lack of awareness amongst
health care workers and patients [45, 48, 50]. In Kenya,
Xpert® sensitisation was initially done for lab staff only,
which could have led to less demand for the test from cli-
nicians. Some studies identified that training, workload,
administrative support, staff motivation, role models and
participation in the guideline development influence the
implementation of TB guidelines in general [51–53].
Patients from higher level facilities had a tendency to-
wards reduced odds of getting an Xpert® done. This
could be because they get patients already being
worked up from lower level facilities being referred to
them to manage complications. The Kenya TB patient
pathway analysis paper found that 58% of patients
sought care in lower level facilities [32]. The Kenya
SARAM report found only 60% of Kenya’s health faci-
lities were ready to provide Kenya Essential Package
for Health-defined TB services [34]. Readiness was
found to be highest at the primary care facilities and in
public facilities [34]. This is unlike in more well-
resourced low TB burden countries, where TB care is
at tertiary level facilities, and most patients have access
to molecular diagnostic tests [54]. Private sector pa-
tients also had a tendency toward reduced odds of get-
ting tested compared to public sector patients. This
Fig. 5 Maps illustrating the distribution of facilities with TB diagnostic capabilities by: Microscopy (a); Xpert MTB/RIF® (b); Culture and Line Probe
Assay Labs (c); and Chest X-ray (d), all overlaying each county’s population density in 2015 as the background
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could be explained by private practice patients having
to pay for tests to be done, and physicians may fail to
comply with national guidelines, as seen in other set-
tings [55–57].
Limitations
These data are from notification data which may be incom-
plete because an unknown number of cases may be treated
but not reported. We additionally had no information on
Table 3 Determinants of use Xpert/MTB/RIF® in Kenya
Characteristic 0-14yrs
Xpert® done
n (column %)
N=309
≥15yrs
Xpert® done
n (column %)
N=9,224
Model 1
0-14yrs
adjusted OR
(95% CI)
N=6,450
Model 2
≥15yrs
adjusted OR
(95% CI)
N=75,845
Model 3
Overall
adjusted OR
(95% CI)
N=82,295
Age 1 (≥15yrs base)
0.41 (0.36 to 0.47)
Gender
Female 140 (45.3) 3241 (35.1) 1 (base) 1 (base) 1 (base)
Male 169 (54.7) 5983 (64.9) 1.13 (0.88 to 1.45) 1.09 (1.03 to 1.14) 1.09 (1.03 to 1.14)
HIV Status
Negative 164 (53.1) 4751 (51.5) 1 (base) 1 (base) 1 (base)
Positive 143 (46.3) 4372 (47.4) 2.00 (1.52 to 2.61) 1.83 (1.74 to 1.93) 1.82 (1.73 to 1.92)
Unknown 2 (0.7) 101 (1.1) 0.19 (0.05 to 0.78) 0.81 (0.65 to 1.01) 0.76 (0.61 to 0.94)
Nutrition Status
Normal 40 (12.9) 3379 (36.6) 1 (base) 1 (base) 1 (base)
Underweight 238 (77.0) 5132 (55.6) 1.97 (1.36 to 2.83) 1.13 (1.07 to 1.19) 1.15 (1.09 to 1.21)
Overweight/obese 3 (1.0) 360 (3.9) 0.94 (0.26 to 3.36) 0.88 (0.77 to 0.99) 0.88 (0.78 to 1.00)
Unknown 28 (9.1) 353 (3.8) 1.34 (0.79 to 2.27) 0.64 (0.56 to 0.73) 0.67 (0.59 to 0.76)
Type of patient
New patient/transfer in 277 (89.6) 6497 (70.4) 1 (base) 1 (base) 1 (base)
Relapse/Default/Failure 32 (10.4) 2727 (29.6) 4.19 (2.60 to 6.75) 7.97 (7.47 to 8.50) 7.81 (7.33 to 8.33)
Sector
Public 242 (78.3) 7692 (83.4) 1 (base) 1 (base) 1 (base)
Private 62 (20.1) 1373 (14.9) 0.93 (0.63 to 1.37) 0.85 (0.75 to 0.97) 0.85 (0.75 to 0.97)
FBOsa 5 (1.6) 159 (1.7) 0.62 (0.19 to 2.11) 0.99 (0.67 to 1.46) 0.99 (0.68 to 1.45)
Health Facility Level
Lower levelb 174 (56.3) 5737 (62.2) 1 (base) 1 (base) 1 (base)
Higher levelc 120 (38.8) 3165 (34.3) 1.18 (0.80 to 1.74) 0.91 (0.79 to 1.05) 0.91 (0.79 to 1.06)
Unknown 15 (4.9) 322 (3.5) 1.99 (1.01 to 3.92) 1.01 (0.82 to 1.26) 1.04 (0.84 to 1.28)
Patient from an Xpert® site
Not from Xpert® site 228 (73.8) 6778 (73.5) 1 (base) 1 (base) 1 (base)
From Xpert® site 81 (26.2) 2446 (26.5) 1.17 (0.74 to 1.85) 2.30 (1.86 to 2.82) 2.23 (1.82 to 2.74)
County Poverty Levels (from poorest to richest)
Quartile 1 53 (17.2) 1839 (19.9) 1 (base) 1 (base) 1 (base)
Quartile 2 78 (25.2) 2875 (31.2) 0.85 (0.39 to 1.86) 1.22 (0.60 to 2.48) 1.19 (0.60 to 2.37)
Quartile 3 103 (33.3) 2802 (30.4) 1.04 (0.48 to 2.26) 1.34 (0.66 to 2.74) 1.32 (0.66 to 2.62)
Quartile 4 75 (24.3) 1708 (18.5) 0.54 (0.25 to 1.18) 0.64 (0.32 to 1.27) 0.62 (0.32 to 1.21)
Intra-class correlation coefficients (ICC)
County 0.04 (0.02 to 0.11) 0.07 (0.04 to 0.11) 0.07 (0.04 to 0.11)
Health facility 0.26 (0.18 to 0.37) 0.24 (0.21 to 0.27) 0.24 (0.21 to 0.27)
aFBOs Faith Based Organisations
bPrimary referral facilities
cSecondary and tertiary referral facilities
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those in whom a test was done and not documented, or in
whom a test was attempted but failed. A large proportion
of relevant cases probably had no record of a test being
done and no indication of why a test was not done.
This work, however, still provides much needed insights
about the utilisation of diagnostic tests amongst those
accessing health care who have been diagnosed and started
on TB treatment. It also contrasts with the prevalence sur-
vey, where up to 40% of TB cases were missed and, thus,
got no TB diagnostic tests. The guidelines recommend
that all patients should have a bacteriological test prior to
treatment. We evaluated, with the information available,
how well the guidelines were being followed.
Our complete case analysis dropped approximately 3%
of the cases due to missing data on facility, but this did
not reduce our ability to make meaningful inferences.
We also considered all the 0-14yrs old as a single group
but there may be differences in the sub categories. Be-
cause the numbers of children were low, subgroup ana-
lysis could have been misleading. This analysis together
with the prevalence survey still provide deep insights
into the known TB cases and guideline adherence, which
can aid in planning services to improve TB case detec-
tion, especially in children.
Conclusions
Underuse of Xpert® despite wide scale roll out and con-
siderable investments undermines assertions of the
cost-effectiveness of this technology. There is need to
increase use of Xpert®, to ensure the correct patients
are targeted for lengthy and potentially toxic TB treat-
ment, and so that its potential advantages are realised
and investments justified. Current focus on increasing
access to Xpert® is insufficient and more attention needs
to be given to service delivery models that involve and
educate staff and that address potential challenges of pa-
tient and specimen referral, with consideration needed for
the private sector. Further research can support such ef-
forts by identifying barriers and testing strategies to over-
come these.
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